Capricor Therapeutics (NASDAQ:CAPR) Given Neutral Rating at Roth Capital

Roth Capital reissued their neutral rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research report report published on Friday,Benzinga reports. The firm currently has a $10.50 price target on the biotechnology company’s stock, up from their prior price target of $7.00.

Several other research analysts also recently commented on CAPR. Ladenburg Thalmann & Co. Inc. downgraded shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, July 30th. Oppenheimer reissued an “outperform” rating on shares of Capricor Therapeutics in a research report on Thursday, October 8th. HC Wainwright lowered shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, July 27th. B. Riley Financial raised shares of Capricor Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $5.00 to $21.00 in a report on Monday, September 14th. Finally, Cantor Fitzgerald upgraded shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Friday, August 14th. Five research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $30.09.

Capricor Therapeutics Price Performance

Shares of Capricor Therapeutics stock opened at $9.53 on Friday. The business’s 50 day simple moving average is $8.10 and its two-hundred day simple moving average is $19.85. The stock has a market capitalization of $554.09 million, a P/E ratio of -3.61 and a beta of 0.80. Capricor Therapeutics has a one year low of $2.96 and a one year high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Tuesday, November 10th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.29). Sell-side analysts expect that Capricor Therapeutics will post -2.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

Several hedge funds have recently made changes to their positions in CAPR. KBC Group NV bought a new position in shares of Capricor Therapeutics during the first quarter valued at approximately $44,000. Activest Wealth Management boosted its holdings in Capricor Therapeutics by 100.0% in the third quarter. Activest Wealth Management now owns 4,000 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 2,000 shares in the last quarter. Quantinno Capital Management LP boosted its holdings in Capricor Therapeutics by 16.8% in the first quarter. Quantinno Capital Management LP now owns 14,472 shares of the biotechnology company’s stock valued at $440,000 after acquiring an additional 2,083 shares in the last quarter. Russell Investments Group Ltd. increased its position in Capricor Therapeutics by 21.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 17,326 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 3,036 shares during the period. Finally, Sei Investments Co. increased its position in Capricor Therapeutics by 41.2% during the 1st quarter. Sei Investments Co. now owns 17,805 shares of the biotechnology company’s stock valued at $541,000 after purchasing an additional 5,195 shares during the period. 21.68% of the stock is owned by hedge funds and other institutional investors.

About Capricor Therapeutics

Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company’s leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.